Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abbott Humira

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Abbott's lead project, TNF-alpha inhibitor Humira (adalimumab, D2E7), clears FDA Dec. 31 for reducing signs and symptoms and inhibiting the progression of structural damage in adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more disease-modifying anti-rheumatics. Abbott is highlighting convenience of once-weekly dosing, efficacy in reducing structural joint damage and price to encourage switching RA patients from Amgen/Wyeth's Enbrel (etanercept) and J&J's Remicade (infliximab). Enbrel and Remicade carry more indications; Abbott plans to begin filing for five additional indications in 2004. Supply of the biologic is adequate, Abbott say

You may also be interested in...



Abbott Files First Humira sBLA, AstraZeneca Seeks IV Nexium; More Filings

Abbott has kicked off its planned label expansion program for Humira with an Oct. 1 filing for an improved physical function claim in rheumatoid arthritis.

India To Scrap Intellectual Property Appellate Board: Should Pharma Worry?

Legal experts tell the Pink Sheet why India’s plans to abolish the Intellectual Property Appellate Board and shift its powers to courts may be problematic for stakeholders, including those pursuing infringement charges. The transition could mean a significant burden on courts both in terms of capability and capacity, and IPR cases will now conflate into all other pending commercial matters, some experts said, though others cheered the proposed change.

QUOTED. 5 March 2021. Dedi Gilad.

Tyto Care’s remote monitoring and telehealth platform has seen rising demand since the start of the pandemic and the company continues to expand. This week, it announced it raised $50m in a series D financing round. See what Dedi Gilad, CEO of Tyto Care, said about it here.

Topics

UsernamePublicRestriction

Register

OM017181

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel